Member Info for Patagucci

“Become CEO of a new company”

So that would imply replacing RM? Unless you can 2 CEO’s? One for the American and one for the English parts to the company?

Emailing them now I don’t think is really needed. They said results will be early Q1 2022, we are currently in that so everything is on time and I believe they will be having enough to deal with without having to email back investors and repeating what has already been said.

Does anyone else think this video may almost be to do with Activ2… a smile to the US. many of the anti virals on that program were targeted at a certain strain of COVID. Whilst SNG is broad spectrum. Or am I reading into that too much. Almost trying to show why SNG has its place and is needed ASAP.

Sometimes people need to chill on this forum, I’m long on Synairgen, just asking a question. This was posted a few before that trade

31-Jan-22 17:14:02 192.21501 1,545 Sell* 192.00 193.00 2,970

So that’s also at 192/193… but a sell, so are you all saying that’s a mistake?

Doesn't it say unknown regarding the buy/sell?

But I’d take £3 right now!

Hmm but the UK FTSE AIM equivalent price is around £3 I believe?

I always thought AIM was for companies at an early stage, but FTSE250 was when they were more established. Which is why I find it surprising BOO haven’t moved…
I presume if SNG did get into FTSE250, due to ETF’s people buy into it would cause the SP to increase even further on that alone.

*Why would a company such as Boohoo NOT ...

Forgive me I am fairly new to investing, but why would a company such as Boohoo already be in the FTSE250 if its market cap is just under 1.7bn?

The thing is synairgen isn’t a cheap drug. We know that. Someone correct me but we talking in the region of £2000 per course of tx?
But when you see the cost of intensive care, the long term harm covid causes people, the lives which can potentially be saved and the benefit for not just covid but also in tje fight against future respiratory viruses. Does that price not seem a little more justifiable?

Yes all the right signs are being given out by the company. And to add, UK life sciences have Synairgen added to their list.
Just patiently waiting now, the entire market is down, it was fairly obvious where this was heading following the news and trend this weekend. No concerns from me yet, in fact I made another small top up.

£1.89 with no RNS.

Falling market and without news this will drop but nothing to worry about. RNS will be giving a totally different result.

People on here are convinced this share is the next big thing. I’m fairly new to researching this company but certainly looks good.

But apart from this forum there doesn’t seem much love for this stock? I like using Twitter and YouTube to see popularity of a stock.
Does it bother anyone, or do you see it as this isn’t going to get much attention until it’s too late for investors, as in its already run up.

I had a question I wanted answering, and asked fairly. I’m not a de ramper or trying to find flaws in the company, I had a question I didn’t know the answer to.

Schrow you probably know everything there is to know about this company, hence your response. But reacting how you did to my question is probably a good reflection on who you are as a person.

Anyway, thank you all for answering my question and good luck to all synairgen investors. Be nice, we are all on the same team here.

But why would the US government spend millions on a trial if Sprinter results are enough anyway?

I said ‘delayed’ as although technically anything in Q1 is on time, if they have results which they do, but haven’t released them yet it feels like a delay.

Abs you say P3, but is this Sprinter or Activ 2… both are P3, but if positive sprinter which we hope is announced any day now, will that be enough for an EUA, or do you think it is Activ 2 which will have to be successful for the EUA as that is US’s own phase 3 trial.

Do people think this is because of Sprinter results or to do with Activ 2? Or kind of both, knowing the sprinter results means they can predict the Activ 2 results.

Also what’s the advantage of being based in US? Tax benefit, American company so better image to the public or just easier with logistics?

Part of me also wonders with this ‘delayed’ sprinter RNS, is it due to dotting I’s and crossing T’s regarding what comes next with orders for the drug. Mother of all RNS (Sprinter results and EUA) would be life changing for us share holders.

Really thought today would be the day, I’ll check in same place same time tomorrow. Another day closer folks.

This is one of the few Mondays I didn’t expect it with the US bank holiday today…